Psych Congress 2019: Clinicians Struggle with Cannabidiol Reputation


How can clinicians treat individuals with proof-primarily based techniques when they do not reflect the reality they see each day in their practice? Extra generally than not, physicians are faced producing clinical choices primarily based on a small proof to assistance a patient. Quite a few individuals currently self-treat symptoms—ranging from insomnia, to anxiousness, to depression—using cannabinoids, in particular cannabidiol (CBD).

What proof is there that this will assist? What are the dangers? What doses of CBD really should they be applying? What route? How will CBD interact with other drugs? Andrew Penn, RN, MS, NP, CNS, APRN-BC will be exploring these concerns in his speak “Confused about Cannabidiol: A Scientific and Rational Examination of its Dangers and Positive aspects in Psychiatry” at Psych Congress in San Diego, California subsequent month.

Dr. Penn will commence by reviewing the endocannabinoid program and its function in fine-tuning a number of other neurotransmitter systems. Quite a few physicians are not as knowledgeable about the endocannabinoid program as they are with extra properly-identified systems such as serotonin. But obtaining a standard understanding of the CB1 receptors and the two major endocannabinoid neorotransmitters: anandamide (AEA) and 1-Arachidonoylglycerol (two-AG) and the general understanding of the compounds and function of Cannabis is crucial to be in a position to successfully treat—and even extra importantly, emotionally connect to—patients struggling with a range issues.

Join the conversation about CBD at the Psyche Congress on October fourth
Confused About Cannabidiol (CBD)? A Scientific and Rational Examination of Its Dangers and Positive aspects in Psychiatry


Latest posts